Literature DB >> 3208120

Cholecystokinin antagonist lorglumide reverses chronic haloperidol-induced effects on dopamine neurons.

L H Jiang1, R J Kasser, R Y Wang.   

Abstract

Intravenous administration of the cholecystokinin (CCK) antagonist lorglumide (LORG) reversed chronic haloperidol (CHAL)-induced depolarization inactivation (DI) of dopamine (DA) cells in both the A9 and A10 areas. Moreover, microinjection of LORG, but not naloxone, directly into the medial nucleus accumbens (mNAc) dose-dependently reversed CHAL-induced effect. LORG injected into other brain regions was without effect. These results suggest that CCK receptors in the mNAc form an important link for maintaining CHAL-induced DI of DA cells and that CCK is involved in the therapeutic action of antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208120     DOI: 10.1016/0006-8993(88)90330-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Devazepide, a CCKA receptor antagonist, impairs the acquisition of conditioned reward and conditioned activity.

Authors:  S A Josselyn; V P Franco; F J Vaccarino
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

2.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.